Analysis

Mid-afternoon market update: Dow surges over 100 points, Harmony Biosciences shares spike higher

Toward the end of trading Tuesday, the Dow traded up 0.33% to 35,374.03 while the NASDAQ rose 0.54% to 15,103.67. The S&P also rose, gaining 0.55% to 4,511.35.

The U.S. has the highest number of coronavirus cases and deaths in the world, reporting a total of 45,908,210 cases with around 746,500 deaths. India confirmed a total of at least 34,094,370 cases and 452,480 deaths, while Brazil reported over 21,651,910 COVID-19 cases with 603,520 deaths. In total, there were at least 242,021,450 cases of COVID-19 worldwide with more than 4,923,690 deaths, according to data compiled by Johns Hopkins University.

Leading and Lagging Sectors

Health care shares gained by 1.3% on Tuesday. Meanwhile, top gainers in the sector included HCW Biologics Inc. HCWB +13.78% (Get Free Alerts for HCWB), up 16% and Ginkgo Bioworks Holdings, Inc. DNA +20.21% (Get Free Alerts for DNA) up 15%.

In trading on Tuesday, consumer staples shares fell 0.2%.

Top Headline

Johnson & Johnson JNJ +2.4% reported better-than-expected earnings for its third quarter and raised its FY21 forecast.

Johnson & Johnson reported quarterly earnings of $2.60 per share, beating analysts’ estimates of $2.36 per share. The company reported quarterly revenue of $23.34 billion, versus analysts’ estimates of $23.74 billion.

Johnson & Johnson raised FY21 guidance to overall sales of $94.1 billion - $94.6 billion ($93.8 billion - $94.6 billion previously), including $2.5 billion from COVID-19 vaccine sales. It expects adjusted EPS of $9.77-$9.82, as against the earlier outlook of $9.60 - $9.70, higher than the consensus of $9.66.

Equities Trading UP

HCW Biologics Inc. HCWB +13.78% (Get Free Alerts for HCWB) shares shot up 16% to $3.30.

Shares of Harmony Biosciences Holdings, Inc. HRMY +10.18% got a boost, shooting 12% to $42.72 after it was announced the company will replace Retail Properties of America in the S&P SmallCap 600.

InflaRx N.V. IFRX +14.46% shares were also up, gaining 11% to $2.6750 after the company announced it was awarded an up to roughly $50.7 million grant by the German government to advance the development of vilobelimab for the treatment of severe COVID-19.

Equities Trading DOWN

Galera Therapeutics, Inc. GRTX -69.59% shares tumbled 70% to $2.1915 in reaction to disappointing data from the Phase 3 ROMAN trial of avasopasem manganese in severe oral mucositis (SOM) patients with locally advanced head and neck cancer (HNC) undergoing standard-of-care radiotherapy.

Shares of Atea Pharmaceuticals, Inc. AVIR -65.96% were down 63% to $15.09 after the company reported data from the Phase 2 MOONSONG trial of AT-527 in the outpatient setting in patients with mild or moderate COVID-19. The trial did not meet the primary endpoint of clear reduction in SARS-CoV-2 viral load in the overall population compared to placebo.

EverQuote, Inc. EVER -13.44% was down, falling 13% to $15.00 after the company cut third-quarter sales guidance below estimates.

Commodities

In commodity news, oil traded up 1% to $83.28, while gold traded up 0.3% to $1,770.20.

Silver traded up 2.3% Tuesday to $23.79 while copper fell 0.5% to $4.7020.

Euro zone

European shares closed mostly higher today. The eurozone’s STOXX 600 gained 0.33%, the Spanish Ibex Index rose 0.67% and the German DAX 30 gained 0.27%. Meanwhile, the London’s FTSE 100 rose 0.19%, French CAC 40 slipped 0.05% and Italy’s FTSE MIB gained 0.25%.

Spanish trade deficit widened to EUR 3.87 billion in August from a EUR 1.73 billion gap in the year-ago month.

Economics

Housing starts dropped by 1.6% to an annual rate of 1.555 million in September, while building permits fell 7.7% to an annual rate of 1.589 million.

Information on these pages contains forward-looking statements that involve risks and uncertainties. Markets and instruments profiled on this page are for informational purposes only and should not in any way come across as a recommendation to buy or sell in these assets. You should do your own thorough research before making any investment decisions. FXStreet does not in any way guarantee that this information is free from mistakes, errors, or material misstatements. It also does not guarantee that this information is of a timely nature. Investing in Open Markets involves a great deal of risk, including the loss of all or a portion of your investment, as well as emotional distress. All risks, losses and costs associated with investing, including total loss of principal, are your responsibility. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of FXStreet nor its advertisers.


RELATED CONTENT

Loading ...



Copyright © 2024 FOREXSTREET S.L., All rights reserved.